Robert I. Blum, President and CEO of Cytokinetics Inc, filed a Form 4 on November 18, 2026, disclosing the exercise of a stock option and the sale of common stock on November 16, 2026, pursuant to a Rule 10b5-1 trading plan.
Key Highlights
- Option exercise: Blum acquired 7,500 shares of common stock via a non-qualified stock option at an exercise price of $10.60 per share on November 16, 2026.
- Shares sold: A total of 7,500 shares were sold across three tranches: 5,077 shares at a weighted average of $53.22, 2,223 shares at a weighted average of $54.08, and 200 shares at a weighted average of $55.21.
- Direct beneficial ownership: Following the transactions, Blum directly owned 278,544 shares of common stock.
- Remaining option position: Blum held 126,745 non-qualified stock options (right to buy) after the reported transaction, with an expiration date of February 28, 2027.
- Rule 10b5-1 plan: The filing indicates the transactions were made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c).
- Indirect holdings disclaimed: Blum is listed as co-trustee of two irrevocable trusts holding 2,083 shares each, but the filing states beneficial ownership is disclaimed for both.
Details of Blum's November 16 Option Exercise and Share Sales at Cytokinetics
According to the filing, Robert I. Blum, who serves as both a Director and President and CEO of Cytokinetics Inc (NASDAQ:CYTK), reported a same-day option exercise and share sale on November 16, 2026. The exercise involved 7,500 shares acquired under a non-qualified stock option originally exercisable as of March 28, 2017, with an exercise price of $10.60 per share and an expiration date of February 28, 2027. Following the exercise, the filing records an acquisition of 7,500 shares at the $10.60 exercise price, bringing directly owned shares to 286,044 before the sales.
The filing discloses three separate sale tranches on the same date. The first involved 5,077 shares sold at a weighted average price of $53.22, with individual transaction prices ranging from $52.80 to $53.80. The second tranche covered 2,223 shares at a weighted average of $54.08, with prices from $53.80 to $54.46. The third tranche covered 200 shares at a weighted average of $55.21, with prices from $54.94 to $55.59. After all three sales, Blum's direct beneficial ownership stood at 278,544 shares, according to the filing.
The filing also notes that Blum holds shares indirectly as co-trustee of The Bridget Blum 2003 Irrevocable Trust (2,083 shares) and The Brittany Blum 2003 Irrevocable Trust (2,083 shares), but states that "Beneficial Ownership disclaimed" for both trusts. A third trust is listed with zero shares. The form was signed by Jeff Hessekiel as attorney-in-fact for Mr. Blum on November 18, 2026.
What Was Disclosed
The filing reports a November 16, 2026 exercise of 7,500 stock options at $10.60 per share and the subsequent sale of all 7,500 resulting shares across three price tranches, carried out under a Rule 10b5-1 plan, leaving Blum with 278,544 directly held shares.






Please wait processing your request...